Safety signal detection: The relevance of literature review

Drug Safety

Volumn 37, Issue 7, 2014, Pages 471-479

  Pontes, Helena ^a   Clément, Mallorie ^a   Rollason, Victoria ^b  

^a United Biosource Corporation   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NIFEDIPINE; TAMSULOSIN; THALIDOMIDE;

APLASTIC ANEMIA; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FLOPPY IRIS SYNDROME; HUMAN; IRIS DISEASE; MEDICAL LITERATURE; META ANALYSIS (TOPIC); PHOCOMELIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCREENING; SIGNAL DETECTION; SYSTEMATIC REVIEW (TOPIC); VIRUS REPLICATION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; GOVERNMENT REGULATION; LEGISLATION AND JURISPRUDENCE; LITERATURE; ORGANIZATION AND MANAGEMENT; PATIENT SAFETY; STANDARDS;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPEAN UNION; GOVERNMENT REGULATION; GUIDELINES AS TOPIC; PATIENT SAFETY; PHARMACOVIGILANCE; REVIEW LITERATURE AS TOPIC;

EID: 84904749526     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0180-9     Document Type: Review

References (27)

1. Lu Z. Information technology in pharmacovigilance: benefits, challenges, and future directions from industry perspectives. Drug Healthc Patient Saf. 2009;1:35-45.
2. ICH, Guideline E2C(R2) - periodic benefit-risk evaluation reports; 2012.
3. McBride WG. Thalidomide and congenital abnormalities. Lancet. 1961;278:1358.
4. Lerner KL. Medicine health and bioethics: essential primary sources. Gale; 2006.
5. Ross SD. The role of systematic reviews in pharmacovigilance: a case study of granulocyte-macrophage colonystimulating factor in AIDS. Drug Inf J. 1998;32:639-47. (Pubitemid 28380905)
6. Folks TM, Justement J, Kinter A, Dinarello CA, Fauci AS. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science. 1987;238:800-2.
7. Kitano K, Abboud CN, Ryan DH, Quan SG, Baldwin GC, Golde DW. Macrophage-active colony-stimulating factors enhance human immunodeficiency virus type 1 infection in bone marrow stem cells. Blood. 1991;77:1699-705.
8. Laporte JR, Carne X, Vidal X, Moreno V, Juan J. Upper gastrointestinal bleeding in relation to previous use of analgesics and non-steroidal anti-inflammatory drugs. Catalan Countries Study on Upper Gastrointestinal Bleeding. Lancet. 1991;337:85-9.
9. de Abajo FJ, Rodriguez LA, Montero D. Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study. BMJ. 1999;319:1106-9. (Pubitemid 29494721)
10. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet. 1995;346:1582-8.
11. Jick H, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet. 1995;346:1589-93. (Pubitemid 26001840)
12. Spitzer WO, Lewis MA, Heinemann LA, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Translational Research Group on Oral Contraceptives and the Health of Young Women. BMJ. 1996;312:83-8.
13. Arnaiz JA, Carne X, Riba N, Codina C, Ribas J, Trilla A. The use of evidence in pharmacovigilance. Case reports as the reference source for drug withdrawals. Eur J Clin Pharmacol. 2001;57:89-91. (Pubitemid 32391420)
14. Laporte JR, Ibanez L, Ballarin E, Perez E, Vidal X. Fatal aplastic anaemia associated with nifedipine. Lancet. 1998;352:619-20. (Pubitemid 28380145)
15. Chang DF, Campbell JR. Intraoperative floppy iris syndrome associated with tamsulosin. J Cataract Refract Surg. 2005;3:664-73. (Pubitemid 40719407)
16. Klose J, Fröhling S, Kroth E, Dobmeyer T, Nolting A. Safety information from spontaneous and literature adverse reactions reports: a comparison. Ther Innov Regul Sci. 2013;47:248-55.
17. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): module VII - periodic safety update report. EMA/816292/2011. 2012.
18. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): module VI - management and reporting of adverse reactions to medicinal products. EMA/873138/2011. 2012.
19. Council for International Organizations of Medical Sciences (CIOMS), Working Group IV. Benefit-risk balance for marketed drugs: evaluating safety signals, 1st edn. Geneva: CIOMS; 1998.
20. Pharmacovigilance and Drug Safety [Internet] 2009. http://www. pharmacovigilance.org.uk/tag/literature-screening/.
21. US Food and Drug Administration. Code of Federal Regulations Title 21: Section 314.80 - postmarketing reporting of adverse drug experiences. 21CFR314.80. Silver Spring (MD): US FDA; 2012.
22. European Medicines Agency, Heads of Medicines Agencies. Guideline on good pharmacovigilance practices (GVP): Module I - pharmacovigilance systems and their quality systems. EMA/541760/2011. 2012.
23. Impicciatore P, Mucci M. Completeness of published case reports on suspected adverse drug reactions: evaluation of 100 reports from a company safety database. Drug Saf. 2010;33:765-73.
24. Hopewell S, Clarke M, Lefebvre C, Scherer R. Handsearching versus electronic searching to identify reports of randomized trials. Cochrane Database Syst Rev. 2007; (2):MR000001.
25. The Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Oxford: The Cochrane Collaboration; 2011.
26. Shabajee N, Lamb EJ, Sturgess I, Sumathipala R. Omeprazole and refractory hypomagnesaemia. BMJ. 2008;337:a425.
27. Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP. Guidelines for submitting adverse event reports for publication. Drug Saf. 2007;30:367-73. (Pubitemid 46740334)